Breast Cancer: The Importance of Local Control

Publication
Article
OncologyONCOLOGY Vol 11 No 12
Volume 11
Issue 12

Award-winning work by Dr. Marie Overgaard, of the Department of Oncology, Aarhus University Hospital, Denmark, gives new hope of longer survival for women with breast cancer. Dr. Overgaard’s work shows that treating the primary

Award-winning work by Dr. Marie Overgaard, of the Department of Oncology, Aarhus University Hospital, Denmark, gives new hope of longer survival for women with breast cancer. Dr. Overgaard’s work shows that treating the primary tumor with an optimal combination of surgery, radiotherapy and adjuvant chemotherapy markedly reduces the risk of local recurrences. Dr. Overgaard therefore calls for the reversal of current trends towards less aggressive local treatment for primary breast cancers.

Over the past 25 years, major improvements in survival from breast cancer have been achieved by giving adjuvant therapy,” said Dr. Overgaard at the 1997 European Cancer Conference. “But, paradoxically, there has been a tendency to treat the primary tumor less aggressively than before, on the basis that breast cancer is a systemic disease and that local treatment to the primary tumor will not affect survival.”

The Danish Breast Cancer Trials show that this view is mistaken. In these trials, 3,000 premenopausal and postmenopausal women received postmastectomy radiation and adjuvant systemic therapy, or systemic adjuvant therapy alone. Strikingly, during the 10-year follow-up period, the women who received systemic adjuvant therapy alone were four times more likely to develop local recurrences than the women who received combined therapy. 

Recent Videos
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.